See more : Cizzle Biotechnology Holdings Plc (CIZ.L) Income Statement Analysis – Financial Results
Complete financial analysis of Centogene N.V. (CNTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Centogene N.V., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Kovai Medical Center and Hospital Limited (KOVAI.NS) Income Statement Analysis – Financial Results
- Cal Bay International, Inc. (CBYI) Income Statement Analysis – Financial Results
- AB Electrolux (publ) (ELUX-B.ST) Income Statement Analysis – Financial Results
- Australia and New Zealand Banking Group Ltd (AN3PH.AX) Income Statement Analysis – Financial Results
- Zhengwei Group Holdings Company Limited (2147.HK) Income Statement Analysis – Financial Results
Centogene N.V. (CNTG)
About Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 47.54M | 47.47M | 189.92M | 128.38M | 48.78M | 40.48M | 31.69M | 27.67M |
| Cost of Revenue | 35.93M | 27.71M | 161.77M | 86.38M | 26.01M | 19.94M | 14.94M | 12.86M |
| Gross Profit | 11.61M | 19.76M | 28.16M | 42.00M | 22.78M | 20.54M | 16.75M | 14.81M |
| Gross Profit Ratio | 24.42% | 41.63% | 14.83% | 32.72% | 46.69% | 50.74% | 52.86% | 53.54% |
| Research & Development | 10.17M | 17.49M | 19.30M | 14.94M | 9.59M | 6.30M | 6.40M | 5.89M |
| General & Administrative | 29.17M | 29.21M | 44.79M | 37.67M | 23.16M | 18.61M | 9.50M | 8.89M |
| Selling & Marketing | 12.56M | 9.92M | 9.86M | 7.58M | 9.25M | 7.47M | 5.90M | 5.36M |
| SG&A | 41.68M | 39.13M | 54.65M | 45.25M | 32.41M | 26.08M | 15.40M | 14.25M |
| Other Expenses | 1.91M | -340.00K | -970.00K | -2.22M | 109.00K | -2.14M | 0.00 | 290.51K |
| Operating Expenses | 49.93M | 56.28M | 72.98M | 57.96M | 42.11M | 30.25M | 21.28M | 19.21M |
| Cost & Expenses | 85.86M | 83.99M | 234.74M | 144.34M | 68.12M | 50.19M | 36.22M | 32.07M |
| Interest Income | 209.00K | 3.00K | 3.00K | 6.00K | 16.00K | 33.00K | 14.00K | 26.00K |
| Interest Expense | 8.20M | 3.57M | 851.00K | 1.04M | 2.03M | 1.08M | 1.02M | 829.00K |
| Depreciation & Amortization | 7.45M | 10.19M | 20.77M | 14.09M | 6.56M | 5.34M | 3.04M | 2.19M |
| EBITDA | -30.87M | -26.00M | -41.03M | -50.12M | -12.74M | -5.40M | -1.29M | -2.94M |
| EBITDA Ratio | -64.93% | -54.77% | -12.39% | -0.64% | -26.12% | -11.12% | -4.04% | -8.28% |
| Operating Income | -38.32M | -36.52M | -44.82M | -15.96M | -19.34M | -10.61M | -4.46M | -4.94M |
| Operating Income Ratio | -80.61% | -76.92% | -23.60% | -12.43% | -39.64% | -26.20% | -14.06% | -17.84% |
| Total Other Income/Expenses | 3.08M | -1.82M | -4.22M | 32.63M | -1.36M | -1.94M | -1.01M | -741.00K |
| Income Before Tax | -34.23M | -38.60M | -46.88M | -21.10M | -20.70M | -11.65M | -5.46M | -5.77M |
| Income Before Tax Ratio | -71.99% | -81.30% | -24.68% | -16.43% | -42.43% | -28.78% | -17.24% | -20.84% |
| Income Tax Expense | 281.12K | 107.00K | -24.00K | 281.00K | 158.00K | -310.00K | 14.00K | -408.00K |
| Net Income | -34.80M | -38.70M | -46.85M | -21.38M | -20.86M | -11.34M | -5.48M | -5.36M |
| Net Income Ratio | -73.21% | -81.53% | -24.67% | -16.65% | -42.75% | -28.01% | -17.28% | -19.37% |
| EPS | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| EPS Diluted | -1.24 | -1.44 | -2.09 | -1.02 | -1.27 | -0.57 | -0.28 | -0.27 |
| Weighted Avg Shares Out | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
| Weighted Avg Shares Out (Dil) | 28.16M | 26.81M | 22.44M | 20.91M | 16.41M | 19.86M | 19.86M | 19.86M |
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort
Centogene shares jump on joint venture with Lifera
CENTOGENE to Participate in Upcoming Conferences in May
CENTOGENE to Participate in Upcoming Conferences in April
CENTOGENE to Participate in Upcoming Conferences in March
CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
CENTOGENE to Participate in Upcoming Conferences in December
Source: https://incomestatements.info
Category: Stock Reports